Literature DB >> 18989773

Introduction: Vasopressin therapy.

David J Whellan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18989773     DOI： 10.1007/s10741-008-9116-8

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


× No keyword cloud information.
  4 in total

1.  Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.

Authors:  Liviu Klein; Christopher M O'Connor; Jeffrey D Leimberger; Wendy Gattis-Stough; Ileana L Piña; G Michael Felker; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade
Journal:  Circulation       Date:  2005-05-02       Impact factor: 29.690

Review 2.  Vasopressin-receptor antagonists in heart failure.

Authors:  Teresa A Schweiger; Martin M Zdanowicz
Journal:  Am J Health Syst Pharm       Date:  2008-05-01       Impact factor: 2.637

Review 3.  Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia.

Authors:  C V Leier; L Dei Cas; M Metra
Journal:  Am Heart J       Date:  1994-09       Impact factor: 4.749

Review 4.  Hyponatremia and vasopressin antagonism in congestive heart failure.

Authors:  Siva Kumar; Sharon Rubin; Paul J Mather; David J Whellan
Journal:  Clin Cardiol       Date:  2007-11       Impact factor: 2.882
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.